Advertisement

Updated January 12th, 2021 at 11:02 IST

COVID-19: Moderna says immunity created by its vaccine lasts a year

US pharmaceutical company Moderna Inc on January 11 said that the immunity from its mRNA coronavirus vaccine should last at least a year.

Reported by: Bhavya Sukheja
Moderna
| Image:self
Advertisement

US pharmaceutical company Moderna Inc on January 11 said that the immunity from its COVID-19 vaccine should last at least a year. Moderna’s mRNA vaccine has shown 94 per cent efficacy against the highly-infectious disease in the final phase of the clinical trial. While speaking at the JP Morgan Healthcare conference, the drugmaker said that it is confident that its messenger RNA technology it used was well suited to deploy a vaccine based on the new variant of the coronavirus which has emerged in a handful of countries. 

Moderna's COVID-19 vaccine is administered in two doses, 28 days apart. Its mRNA-1273 technology uses synthetic nRNA to mimic the surface of the coronavirus and teach the immune system to recognise and neutralise it. On Monday, the US-based company said that in December it would run tests to confirm the vaccine’s activity against any strain. 

Further, the drugmaker also informed that it is expected to deliver between 600 million doses and one billion doses of its vaccine in 2021. Moderna has forecasted vaccine-related sales of $11.7 billion for the year, based on advance purchase agreements signed with governments across the globe. During the conference, Moderna’s CEO Stéphane Bancel said that his team feels “very comfortable” with the track record they have now. Bancel reiterated that Moderna is on track to deliver at least 600 million doses. 

READ: UK Approves Third COVID-19 Vaccine As Moderna's Jab Gets Green Light

READ: Spain To Receive 1st Batch Of Moderna COVID Vaccine In 7-10 Days, Says Health Minister

Moderna’s vaccine ‘safe and effective’ 

Meanwhile, the UK, EU, Canada and the US have already approved Moderna vaccine based on the results of its trials. According to a study published in the New England Journal of Medicine, Moderna’s vaccine has demonstrated 94.1 per cent efficacy in preventing the highly-infectious disease. The scientists also noted that the severe cases occurred only among the volunteers who received the placebo.

Moderna's vaccine is easier to transport and handle if compared to Pfizer-BioNTech because it doesn't require to be stored at extreme temperatures. The European Medical Agency (EMA) has said that a “very large clinical trial” proved the vaccine is safe and effective and also showed the efficacy of 90.9% in people with chronic lung disease, heart disease, obesity, liver disease, diabetes, or HIV infection. 

READ: COVID-19: European Union Recommends Authorisation Of Moderna's Vaccine

READ: COVID-19: US May Halve Moderna's Vaccine Doses To Inoculate More People
 

Advertisement

Published January 12th, 2021 at 11:04 IST

Your Voice. Now Direct.

Send us your views, we’ll publish them. This section is moderated.

Advertisement
Advertisement

Trending Quicks

Mukhtar Ansari Death
13 minutes ago
Chamkila
16 minutes ago
Lorry Crushes Car-Cleaner To Death In Telangana
21 minutes ago
Major League Cricket
22 minutes ago
Abhay Deol
23 minutes ago
delhi cm arvind kejriwal
25 minutes ago
MEA Responds To China’s Comment On Sikh Separatist Gurupatwant Singh Pannun
27 minutes ago
Riyan Parag
29 minutes ago
David Warner
30 minutes ago
Dhara Gujjar
39 minutes ago
The ICJ has ordered Israel to ensure the smooth flow of aid to the people of Gaza.
44 minutes ago
UFC Exclusive Erin Blanchfield
an hour ago
Advertisement
Advertisement
Advertisement
Whatsapp logo